RecruitingPhase 2NCT03758989

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Sponsor

University of Rochester

Enrollment

40 participants

Start Date

May 8, 2019

Study Type

INTERVENTIONAL

Conditions

DLBCL

Summary

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying a tailored treatment approach for people newly diagnosed with early-stage (limited) diffuse large B-cell lymphoma (DLBCL), where PET scan results guide whether less or more intensive treatment is needed. **You may be eligible if...** - You have been newly diagnosed with limited stage (early, non-bulky) diffuse large B-cell lymphoma (DLBCL) and have not yet received treatment - Patients with grade 3B follicular lymphoma or transformed lymphoma are also eligible - You are 18 years or older - You have measurable disease seen on a PET scan - Your heart and kidney function are adequate **You may NOT be eligible if...** - You have already received treatment for this lymphoma - You have bulky (very large) or advanced-stage lymphoma - You have uncontrolled medical conditions (such as heart failure or unstable angina) - You are pregnant or unable to tolerate chemotherapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRituximab Prednisone

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUGCyclophosphamide

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUGDoxorubicin

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUGVincristine

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUGPrednisone

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Locations(1)

University of Rochester

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03758989

Related Trials

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017121 locations

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT0601476217 locations

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

NCT045127167 locations

A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma

NCT073351201 location

Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

NCT071620121 location